Wilmington PharmaTech ("Wilmington"), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, today announced a $50 ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of ...

EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug ...

China and India, which are the largest producers of APIs for the U.S. drug supply, also account for most of the FDA regulatory actions. Not only do quality problems at Chinese and Indian firms raise ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO).

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production ...